Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:34 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 14,125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Recruiting Phase 3 Interventional

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Trontinemab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
12
States / cities
Irvine, California • Long Beach, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 5:34 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability Evaluation of IgG Binding Protein LT

NCT07824011
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
IgG Binding Protein LT, Placebo
Dietary Supplement
Lead sponsor
Bactolife A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

NCT04527471
View directory record Official record
Conditions
Coronavirus Infection, Covid-19, SARS-CoV-2
Interventions
Ensifentrine Dose 1, Placebo pMDI
Drug
Lead sponsor
Verona Pharma Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Nov 3, 2026, 5:34 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

NCT03880487
View directory record Official record
Conditions
Analgesia
Interventions
KP-1199, Placebo oral capsule, Oxycodone oral capsule
Drug
Lead sponsor
Kalyra Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 3, 2026, 5:34 PM EST
Completed Not applicable Interventional Results available

ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease

NCT01608061
View directory record Official record
Conditions
Alzheimer Disease
Interventions
DBS-f on, DBS-f off
Device
Lead sponsor
Functional Neuromodulation Ltd
Industry
Eligibility
45 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Sun City, Arizona • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Nov 3, 2026, 5:34 PM EST
Not listed Phase 2Phase 3 Interventional

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

NCT00201461
View directory record Official record
Conditions
Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions
STARFlex septal closure system, Best medical therapy
Device · Drug
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2008 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 3 Interventional Results available

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

NCT02319005
View directory record Official record
Conditions
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions
Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome

NCT01332305
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn (XP13512/GSK1838262), Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Nov 3, 2026, 5:34 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
View directory record Official record
Conditions
HIV Infections
Interventions
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 3 Interventional Results available

A Safety and Efficacy Comparison of BLI4700 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

NCT03261960
View directory record Official record
Conditions
Colonoscopy
Interventions
BLI4700, Magnesium bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Nov 3, 2026, 5:34 PM EST
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

NCT07378579
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ESK-001, Moxifloxacin (400 mg), Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 2 Interventional

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Suramin Sodium
Drug
Lead sponsor
Paxmedica
Industry
Eligibility
4 Years to 17 Years · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 3 Interventional Results available

Safety Study of Viaskin Peanut to Treat Peanut Allergy

NCT02916446
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 µg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 5:34 PM EST
Terminated Phase 2 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

NCT03742973
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Coronado, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 3, 2026, 5:34 PM EST
Completed Not applicable Interventional Results available

Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels

NCT00637156
View directory record Official record
Conditions
Cervical Degenerative Disc Disease, Radiculopathy, Myelopathy
Interventions
PRESTIGE LP device at two adjacent levels, Bi-level fusion with ATLANTIS Cervical Plate System
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
29
States / cities
Huntsville, Alabama • Beverly Hills, California • Colton, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Nov 3, 2026, 5:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Fruit And Vegetable Or Recreation Prescriptions for UW-Madison Students

NCT02870322
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Fruit and Vegetable CSA Prescription, Bikeshare Prescription
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 24 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

NCT04707313
View directory record Official record
Conditions
Obesity
Interventions
Placebo (Cohorts 1 and 2), PF-06882961 (Cohorts 1 and 2), Placebo (Cohort 3), PF-06882961 (Cohort 3)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
27
States / cities
Anniston, Alabama • Anaheim, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 3, 2026, 5:34 PM EST
Recruiting Phase 2 Interventional

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296
View directory record Official record
Conditions
Proteinuric Kidney Diseases
Interventions
BI 764198, Placebo matching BI 764198
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Huntsville, Alabama • Glendale, California • Granada Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 5:34 PM EST
Terminated Phase 1 Interventional

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

NCT01559103
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI5117, MEDI5117 Placebo
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
20 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 3 Interventional Results available

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

NCT01537042
View directory record Official record
Conditions
Restless Legs Syndrome, End-Stage Renal Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070
View directory record Official record
Conditions
Pharmacokinetics of ASP2408, Healthy Subjects
Interventions
ASP2408, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Nov 3, 2026, 5:34 PM EST
Completed Phase 4 Interventional Results available

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
View directory record Official record
Conditions
Elective Cesarean Section, Pain Management
Interventions
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Nov 3, 2026, 5:34 PM EST